Epidermolysis Bullosa – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Epidermolysis Bullosa – Pipeline Review, H1 2020’, provides an overview of the Epidermolysis Bullosa pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa

– The report reviews pipeline therapeutics for Epidermolysis Bullosa by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Epidermolysis Bullosa therapeutics and enlists all their major and minor projects

– The report assesses Epidermolysis Bullosa therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Epidermolysis Bullosa

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abeona Therapeutics Inc

Aegle Therapeutics Corp

Almirall SA

Amryt Pharma Plc

Anterogen Co Ltd

APR Applied Pharma Research SA

Berg LLC

BioVec Pharma Inc

BridgeBio Pharma Inc

Castle Creek Biosciences Inc

Celularity Inc

Constant Therapeutics LLC

CSA Biotechnologies LLC

CSL Ltd

Daewoong Pharmaceutical Co Ltd

FIBRX Derm Inc

Holostem Terapie Avanzate Srl

Immusoft Corp

InMed Pharmaceuticals Inc

Krystal Biotech Inc

LambdaGen Therapeutics

Mesoblast Ltd

OTR3 SAS

Palvella Therapeutics LLC

Phoenix Tissue Repair Inc

Quoin Pharmaceuticals Ltd

RegeneRx Biopharmaceuticals Inc

RHEACELL GmbH & Co KG

Shionogi & Co Ltd

StemRIM Inc

Therapicon Srl

Trucode Gene Repair Inc

TWi Biotechnology Inc

Wings Therapeutics

Table of Contents

Table of Contents

Introduction

Epidermolysis Bullosa - Overview

Epidermolysis Bullosa - Therapeutics Development

Epidermolysis Bullosa - Therapeutics Assessment

Epidermolysis Bullosa - Companies Involved in Therapeutics Development

Epidermolysis Bullosa - Drug Profiles

Epidermolysis Bullosa - Dormant Projects

Epidermolysis Bullosa - Discontinued Products

Epidermolysis Bullosa - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Epidermolysis Bullosa, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Epidermolysis Bullosa – Pipeline by Abeona Therapeutics Inc, H1 2020

Epidermolysis Bullosa – Pipeline by Aegle Therapeutics Corp, H1 2020

Epidermolysis Bullosa – Pipeline by Almirall SA, H1 2020

Epidermolysis Bullosa – Pipeline by Amryt Pharma Plc, H1 2020

Epidermolysis Bullosa – Pipeline by Anterogen Co Ltd, H1 2020

Epidermolysis Bullosa – Pipeline by APR Applied Pharma Research SA, H1 2020

Epidermolysis Bullosa – Pipeline by Berg LLC, H1 2020

Epidermolysis Bullosa – Pipeline by BioVec Pharma Inc, H1 2020

Epidermolysis Bullosa – Pipeline by BridgeBio Pharma Inc, H1 2020

Epidermolysis Bullosa – Pipeline by Castle Creek Biosciences Inc, H1 2020

Epidermolysis Bullosa – Pipeline by Celularity Inc, H1 2020

Epidermolysis Bullosa – Pipeline by Constant Therapeutics LLC, H1 2020

Epidermolysis Bullosa – Pipeline by CSA Biotechnologies LLC, H1 2020

Epidermolysis Bullosa – Pipeline by CSL Ltd, H1 2020

Epidermolysis Bullosa – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020

Epidermolysis Bullosa – Pipeline by FIBRX Derm Inc, H1 2020

Epidermolysis Bullosa – Pipeline by Holostem Terapie Avanzate Srl, H1 2020

Epidermolysis Bullosa – Pipeline by Immusoft Corp, H1 2020

Epidermolysis Bullosa – Pipeline by InMed Pharmaceuticals Inc, H1 2020

Epidermolysis Bullosa – Pipeline by Krystal Biotech Inc, H1 2020

Epidermolysis Bullosa – Pipeline by LambdaGen Therapeutics, H1 2020

Epidermolysis Bullosa – Pipeline by Mesoblast Ltd, H1 2020

Epidermolysis Bullosa – Pipeline by OTR3 SAS, H1 2020

Epidermolysis Bullosa – Pipeline by Palvella Therapeutics LLC, H1 2020

Epidermolysis Bullosa – Pipeline by Phoenix Tissue Repair Inc, H1 2020

Epidermolysis Bullosa – Pipeline by Quoin Pharmaceuticals Ltd, H1 2020

Epidermolysis Bullosa – Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2020

Epidermolysis Bullosa – Pipeline by RHEACELL GmbH & Co KG, H1 2020

Epidermolysis Bullosa – Pipeline by Shionogi & Co Ltd, H1 2020

Epidermolysis Bullosa – Pipeline by StemRIM Inc, H1 2020

Epidermolysis Bullosa – Pipeline by Therapicon Srl, H1 2020

Epidermolysis Bullosa – Pipeline by Trucode Gene Repair Inc, H1 2020

Epidermolysis Bullosa – Pipeline by TWi Biotechnology Inc, H1 2020

Epidermolysis Bullosa – Pipeline by Wings Therapeutics, H1 2020

Epidermolysis Bullosa – Dormant Projects, H1 2020

Epidermolysis Bullosa – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Epidermolysis Bullosa, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports